Clinical Trial

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2023 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-27; most recent amendment 2023-07-17.
Trial Details
NCT Number NCT05846750
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Marginal Zone Lymphoma
Enrollment 59 participants
Start Date 2022-11-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2023-07-19